Okyo Pharma Ltd Stock Debt To Equity

OKYO Stock  USD 1.04  0.03  2.97%   
OKYO Pharma Ltd fundamentals help investors to digest information that contributes to OKYO Pharma's financial success or failures. It also enables traders to predict the movement of OKYO Stock. The fundamental analysis module provides a way to measure OKYO Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to OKYO Pharma stock.
Last ReportedProjected for Next Year
Debt To Equity(0.79)(0.83)
As of the 7th of December 2024, Debt To Equity is likely to drop to -0.83.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

OKYO Pharma Ltd Company Debt To Equity Analysis

OKYO Pharma's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

D/E

 = 

Total Debt

Total Equity

More About Debt To Equity | All Equity Analysis

Current OKYO Pharma Debt To Equity

    
  0.02 %  
Most of OKYO Pharma's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, OKYO Pharma Ltd is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

OKYO Debt To Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for OKYO Pharma is extremely important. It helps to project a fair market value of OKYO Stock properly, considering its historical fundamentals such as Debt To Equity. Since OKYO Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of OKYO Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of OKYO Pharma's interrelated accounts and indicators.
0.99-0.80.71-0.47-0.510.80.130.590.73-0.41-0.180.110.2-0.580.25-0.3-0.38-0.530.36
0.99-0.80.76-0.55-0.610.790.140.570.71-0.47-0.270.070.28-0.650.34-0.28-0.46-0.620.43
-0.8-0.8-0.780.420.44-0.86-0.51-0.39-0.940.430.16-0.22-0.270.44-0.310.090.350.47-0.33
0.710.76-0.78-0.68-0.780.740.520.180.7-0.66-0.66-0.170.38-0.840.45-0.26-0.61-0.790.56
-0.47-0.550.42-0.680.86-0.42-0.12-0.14-0.220.350.530.1-0.880.68-0.87-0.080.980.79-0.94
-0.51-0.610.44-0.780.86-0.4-0.15-0.17-0.290.630.710.25-0.680.85-0.780.020.790.89-0.75
0.80.79-0.860.74-0.42-0.40.420.320.77-0.32-0.140.230.27-0.410.29-0.14-0.37-0.420.35
0.130.14-0.510.52-0.12-0.150.42-0.490.52-0.22-0.19-0.040.05-0.220.06-0.1-0.11-0.150.0
0.590.57-0.390.18-0.14-0.170.32-0.490.46-0.18-0.070.00.05-0.250.07-0.14-0.13-0.20.09
0.730.71-0.940.7-0.22-0.290.770.520.46-0.37-0.180.010.04-0.420.08-0.26-0.18-0.330.12
-0.41-0.470.43-0.660.350.63-0.32-0.22-0.18-0.370.720.11-0.130.77-0.27-0.120.250.81-0.18
-0.18-0.270.16-0.660.530.71-0.14-0.19-0.07-0.180.720.55-0.270.86-0.360.080.510.77-0.38
0.110.07-0.22-0.170.10.250.23-0.040.00.010.110.550.160.490.130.430.150.23-0.08
0.20.28-0.270.38-0.88-0.680.270.050.050.04-0.13-0.270.16-0.330.970.39-0.9-0.550.84
-0.58-0.650.44-0.840.680.85-0.41-0.22-0.25-0.420.770.860.49-0.33-0.420.240.620.91-0.52
0.250.34-0.310.45-0.87-0.780.290.060.070.08-0.27-0.360.130.97-0.420.4-0.86-0.620.8
-0.3-0.280.09-0.26-0.080.02-0.14-0.1-0.14-0.26-0.120.080.430.390.240.4-0.08-0.120.08
-0.38-0.460.35-0.610.980.79-0.37-0.11-0.13-0.180.250.510.15-0.90.62-0.86-0.080.72-0.92
-0.53-0.620.47-0.790.790.89-0.42-0.15-0.2-0.330.810.770.23-0.550.91-0.62-0.120.72-0.69
0.360.43-0.330.56-0.94-0.750.350.00.090.12-0.18-0.38-0.080.84-0.520.80.08-0.92-0.69
Click cells to compare fundamentals
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Competition

OKYO Total Stockholder Equity

Total Stockholder Equity

(5.59 Million)

OKYO Pharma reported last year Total Stockholder Equity of (5.88 Million)
According to the company disclosure, OKYO Pharma Ltd has a Debt To Equity of 0.016%. This is 99.97% lower than that of the Biotechnology sector and 99.92% lower than that of the Health Care industry. The debt to equity for all United States stocks is 99.97% higher than that of the company.

OKYO Debt To Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses OKYO Pharma's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of OKYO Pharma could also be used in its relative valuation, which is a method of valuing OKYO Pharma by comparing valuation metrics of similar companies.
OKYO Pharma is currently under evaluation in debt to equity category among its peers.

OKYO Pharma Current Valuation Drivers

We derive many important indicators used in calculating different scores of OKYO Pharma from analyzing OKYO Pharma's financial statements. These drivers represent accounts that assess OKYO Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of OKYO Pharma's important valuation drivers and their relationship over time.
201920202021202220232024 (projected)
Market Cap2.2B2.4B3.5B37.4M43.1M41.0M
Enterprise Value2.2B2.4B3.5B35.6M42.3M40.2M

OKYO Fundamentals

About OKYO Pharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze OKYO Pharma Ltd's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of OKYO Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of OKYO Pharma Ltd based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Pair Trading with OKYO Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if OKYO Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in OKYO Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving against OKYO Stock

  0.45A Agilent TechnologiesPairCorr
  0.4MLSS Milestone ScientificPairCorr
  0.38MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr
  0.31CPIX Cumberland PharmaceuticalsPairCorr
The ability to find closely correlated positions to OKYO Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace OKYO Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back OKYO Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling OKYO Pharma Ltd to buy it.
The correlation of OKYO Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as OKYO Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if OKYO Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for OKYO Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether OKYO Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of OKYO Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Okyo Pharma Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Okyo Pharma Ltd Stock:
Check out OKYO Pharma Piotroski F Score and OKYO Pharma Altman Z Score analysis.
You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OKYO Pharma. If investors know OKYO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OKYO Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.57)
Return On Assets
(2.92)
Return On Equity
(29.69)
The market value of OKYO Pharma is measured differently than its book value, which is the value of OKYO that is recorded on the company's balance sheet. Investors also form their own opinion of OKYO Pharma's value that differs from its market value or its book value, called intrinsic value, which is OKYO Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OKYO Pharma's market value can be influenced by many factors that don't directly affect OKYO Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OKYO Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if OKYO Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OKYO Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.